| Year |
Citation |
Score |
| 2024 |
Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, Zhang Q, Freelander A, Leventhal MJ, Feit A, Cohen Feit G, Feiglin A, Liu W, Hermida-Prado F, Kesten N, ... ... Jeselsohn R, et al. Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38381406 DOI: 10.1158/1078-0432.CCR-23-2975 |
0.565 |
|
| 2024 |
Goldberg J, Qiao N, Guerriero JL, Gross B, Meneksedag Y, Lu YF, Philips AV, Rahman T, Meric-Bernstam F, Roszik J, Chen K, Jeselsohn R, Tolaney SM, Peoples GE, Alatrash G, et al. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-Positive Breast Cancer. Cancer Research Communications. PMID 38335301 DOI: 10.1158/2767-9764.CRC-23-0244 |
0.48 |
|
| 2023 |
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, ... ... Jeselsohn R, et al. Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature Communications. 14: 8321. PMID 38097580 DOI: 10.1038/s41467-023-44124-y |
0.457 |
|
| 2023 |
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, ... ... Jeselsohn R, et al. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature Communications. 14: 7496. PMID 37980405 DOI: 10.1038/s41467-023-43324-w |
0.391 |
|
| 2023 |
Cheng YC, Stein S, Nardone A, Liu W, Ma W, Cohen G, Guarducci C, McDonald TO, Jeselsohn RM, Michor F. Mathematical modeling identifies optimum palbociclib-fulvestrant dose administration schedules for the treatment of estrogen receptor-positive breast cancer patients. Cancer Research Communications. PMID 37921419 DOI: 10.1158/2767-9764.CRC-23-0257 |
0.447 |
|
| 2023 |
Jeselsohn R, Polyak K. HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer. Cell Chemical Biology. 30: 1183-1185. PMID 37863030 DOI: 10.1016/j.chembiol.2023.08.006 |
0.495 |
|
| 2023 |
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, ... ... Jeselsohn R, et al. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4741. PMID 37550302 DOI: 10.1038/s41467-023-40561-x |
0.392 |
|
| 2023 |
Pan M, Solozobova V, Kuznik NC, Jung N, Gräßle S, Gourain V, Heneka YM, Cramer von Clausbruch CA, Fuhr O, Munuganti RSN, Maddalo D, Blattner C, Neeb A, Sharp A, Cato L, ... ... Jeselsohn RM, et al. Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy. Cancer Research Communications. 3: 1378-1396. PMID 37520743 DOI: 10.1158/2767-9764.CRC-23-0111 |
0.806 |
|
| 2023 |
Charles Coombes R, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, ... ... Jeselsohn R, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4444. PMID 37488191 DOI: 10.1038/s41467-023-40061-y |
0.377 |
|
| 2023 |
Fu X, Pereira R, Liu CC, De Angelis C, Shea MJ, Nanda S, Qin L, Mitchell T, Cataldo ML, Veeraraghavan J, Sethunath V, Giuliano M, Gutierrez C, Győrffy B, Trivedi MV, ... ... Jeselsohn R, et al. High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. Cell Reports. 42: 112821. PMID 37467106 DOI: 10.1016/j.celrep.2023.112821 |
0.559 |
|
| 2023 |
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, ... ... Jeselsohn R, et al. Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. Cancer Research. PMID 37450351 DOI: 10.1158/0008-5472.CAN-23-1711 |
0.504 |
|
| 2023 |
Corti C, De Angelis C, Bianchini G, Malorni L, Giuliano M, Hamilton E, Jeselsohn R, Jhaveri K, Curigliano G, Criscitiello C. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? Cancer Treatment Reviews. 117: 102569. PMID 37146385 DOI: 10.1016/j.ctrv.2023.102569 |
0.482 |
|
| 2023 |
Nagy Z, Jeselsohn R. Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer. Frontiers in Oncology. 13: 1155540. PMID 36950546 DOI: 10.3389/fonc.2023.1155540 |
0.525 |
|
| 2023 |
Grinshpun A, Tolaney SM, Burstein HJ, Jeselsohn R, Mayer EL. The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. Npj Breast Cancer. 9: 15. PMID 36949066 DOI: 10.1038/s41523-023-00520-7 |
0.451 |
|
| 2023 |
Nagy Z, Jeselsohn R. ESR1 fusions and therapeutic resistance in metastatic breast cancer. Frontiers in Oncology. 12: 1037531. PMID 36686845 DOI: 10.3389/fonc.2022.1037531 |
0.604 |
|
| 2022 |
Grinshpun A, Sandusky ZM, Jeselsohn R. The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Hematology/Oncology Clinics of North America. 37: 169-181. PMID 36435608 DOI: 10.1016/j.hoc.2022.08.016 |
0.503 |
|
| 2022 |
Grinshpun A, Chen V, Sandusky ZM, Fanning SW, Jeselsohn R. ESR1 activating mutations: From structure to clinical application. Biochimica Et Biophysica Acta. Reviews On Cancer. 1878: 188830. PMID 36336145 DOI: 10.1016/j.bbcan.2022.188830 |
0.543 |
|
| 2022 |
Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, Leshchiner I, Tayob N, Tolaney SM, Tung N, ... ... Jeselsohn R, et al. Clinical Efficacy and Whole Exome Sequencing of Liquid Biopsies in a Phase IB/II study of Bazedoxifene and Palbociclib in Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36215125 DOI: 10.1158/1078-0432.CCR-22-2305 |
0.55 |
|
| 2022 |
Patel JM, Jeselsohn RM. Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. Advances in Experimental Medicine and Biology. 1390: 171-194. PMID 36107319 DOI: 10.1007/978-3-031-11836-4_10 |
0.498 |
|
| 2022 |
Downton T, Zhou F, Segara D, Jeselsohn R, Lim E. Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status. Drug Design, Development and Therapy. 16: 2933-2948. PMID 36081610 DOI: 10.2147/DDDT.S380925 |
0.544 |
|
| 2022 |
Nardone A, Qiu X, Spisak S, Nagy Z, Feiglin A, Feit A, Cohen Feit G, Xie Y, Font-Tello A, Guarducci C, Hermida-Prado F, Syamala S, Lim K, Munoz Gomez M, Pun M, ... ... Jeselsohn R, et al. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Research. PMID 35950920 DOI: 10.1158/0008-5472.CAN-21-3186 |
0.558 |
|
| 2022 |
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, Tirunagaru VG, De Menna M, Paradiso V, Ercan C, Dahmani A, ... ... Jeselsohn RM, et al. Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Communications Biology. 5: 658. PMID 35787660 DOI: 10.1038/s42003-022-03612-5 |
0.523 |
|
| 2022 |
Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. Jama Oncology. PMID 35737367 DOI: 10.1001/jamaoncol.2022.2286 |
0.503 |
|
| 2022 |
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, Tirunagaru VG, De Menna M, Paradiso V, Ercan C, Dahmani A, ... ... Jeselsohn RM, et al. GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Communications Biology. 5: 373. PMID 35440675 DOI: 10.1038/s42003-022-03296-x |
0.599 |
|
| 2021 |
Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, ... ... Jeselsohn R, et al. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications. 12: 5563. PMID 34548479 DOI: 10.1038/s41467-021-25769-z |
0.524 |
|
| 2021 |
De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, ... ... Jeselsohn R, et al. Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4939. PMID 34470810 DOI: 10.1158/1078-0432.CCR-21-2431 |
0.47 |
|
| 2021 |
Qiu X, Feit AS, Feiglin A, Xie Y, Kesten N, Taing L, Perkins J, Gu S, Li Y, Cejas P, Zhou N, Jeselsohn R, Brown M, Shirley Liu X, Long HW. CoBRA: Containerized Bioinformatics Workflow for Reproducible ChIP/ATAC-seq Analysis. Genomics, Proteomics & Bioinformatics. PMID 34284136 DOI: 10.1016/j.gpb.2020.11.007 |
0.377 |
|
| 2021 |
Jeselsohn RM. The evolving use of SERDs in estrogen receptor-positive, HER2-negative metastatic breast cancer. Clinical Advances in Hematology & Oncology : H&O. 19: 428-431. PMID 34236340 |
0.527 |
|
| 2021 |
De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Malorni L, Litchfield LM, ... ... Jeselsohn R, et al. Activation of the interferon signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33536276 DOI: 10.1158/1078-0432.CCR-19-4191 |
0.553 |
|
| 2021 |
Dhimolea E, de Matos Simoes R, Kansara D, Al'Khafaji A, Bouyssou J, Weng X, Sharma S, Raja J, Awate P, Shirasaki R, Tang H, Glassner BJ, Liu Z, Gao D, Bryan J, ... ... Jeselsohn R, et al. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell. PMID 33417832 DOI: 10.1016/j.ccell.2020.12.002 |
0.552 |
|
| 2020 |
Dhimolea E, de Matos Simoes R, Kansara D, Weng X, Sharma S, Awate P, Liu Z, Gao D, Mitsiades N, Schwab JH, Chen Y, Jeselsohn R, Culhane AC, Brown M, Georgakoudi I, et al. Pleiotropic mechanisms drive endocrine resistance in the three-dimensional bone microenvironment. Cancer Research. PMID 32859606 DOI: 10.1158/0008-5472.Can-20-0571 |
0.597 |
|
| 2020 |
Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, Feit AS, Bergholz J, Michowski W, Otto T, Sheng Q, Loo A, Michael W, Tiedt R, DeAngelis C, ... ... Jeselsohn R, et al. Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Science Advances. 6: eabb2210. PMID 32704543 DOI: 10.1126/Sciadv.Abb2210 |
0.681 |
|
| 2020 |
Andreano KJ, Baker JG, Park S, Safi R, Artham S, Oesterreich S, Jeselsohn R, Brown M, Sammons S, Wardell SE, Chang CY, Norris JD, McDonnell DP. The dysregulated pharmacology of clinically relevant ESR1 mutants is normalized by ligand-activated WT receptor. Molecular Cancer Therapeutics. PMID 32381587 DOI: 10.1158/1535-7163.Mct-19-1148 |
0.688 |
|
| 2020 |
Fu X, Pereira R, Angelis CD, Nanda S, Qin L, Veeraraghavan J, Selenica P, Weigelt B, Reis-Filho JS, Nardone A, Jeselsohn R, Brown M, Rimawi MF, Osborne CK, Schiff R. Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd7-01 |
0.687 |
|
| 2020 |
Angelis CD, Cataldo ML, Nardone A, Veeraraghavan J, Fu X, Nanda S, Qin L, Sethunath V, Pereira R, Weigelt B, Reis-Filho JS, Rimawi MF, Jeselsohn R, Osborne K, Schiff R. Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd2-02 |
0.462 |
|
| 2020 |
Fu X, Pereira R, Angelis CD, Nanda S, Qin L, Shea MJ, Mitchell T, Veeraraghavan J, Sethunath V, Gutierrez C, Győrffy B, Cohen O, Wagle N, Nardone A, Jeselsohn R, et al. Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-04-02 |
0.711 |
|
| 2020 |
Jeselsohn R. Abstract MS2-2: Targeting the cell cycle - Beyond CDK4/6 inhibition Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ms2-2 |
0.503 |
|
| 2020 |
Angelis CD, Fu X, Cataldo ML, Nardone A, Jansen VM, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Pereira R, Benelli M, Migliaccio I, Malorni L, Donaldson J, Selenica P, ... ... Jeselsohn R, et al. Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs2-01 |
0.614 |
|
| 2020 |
Stein S, Nardone A, Liu W, Cohen G, Guarducci C, Brown M, Jeselsohn R, Michor F. Abstract B16: Mathematical modeling identifies optimum palbociclib dosing schedules for the treatment of estrogen receptor-positive (ER+) breast cancer patients Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-B16 |
0.695 |
|
| 2019 |
Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, ... ... Jeselsohn R, et al. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 31826955 DOI: 10.1073/Pnas.1911584116 |
0.741 |
|
| 2019 |
Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Bartlett CH, Koehler M, Winer EP, Burstein HJ. A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31250880 DOI: 10.1093/Annonc/Mdz198 |
0.559 |
|
| 2019 |
Chi D, Singhal H, Li L, Xiao T, Liu W, Pun M, Jeselsohn R, He H, Lim E, Vadhi R, Rao P, Long H, Garber J, Brown M. Estrogen receptor signaling is reprogrammed during breast tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. PMID 31110002 DOI: 10.1073/Pnas.1819155116 |
0.796 |
|
| 2019 |
Ligibel J, Dillon DA, Giobbie-Hurder A, McTiernan A, Frank ES, Cornwell M, Pun M, Campbell N, Dowling RJO, Chang MC, Tolaney SM, Chagpar AB, Yung R, Freedman RA, Dominici LS, ... ... Jeselsohn R, et al. Impact of a pre-operative exercise intervention on breast cancer proliferation and gene expression: Results from the Pre-Operative Health and Body (PreHAB) Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31018921 DOI: 10.1158/1078-0432.Ccr-18-3143 |
0.639 |
|
| 2019 |
Hinohara K, Wu HJ, Sébastien Vigneau, McDonald TO, Igarashi KJ, Yamamoto KN, Madsen T, Fassl A, Egri SB, Papanastasiou M, Ding L, Peluffo G, Cohen O, Kales SC, Lal-Nag M, ... ... Jeselsohn R, et al. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 35: 330-332. PMID 30753830 DOI: 10.1016/j.ccell.2019.01.012 |
0.477 |
|
| 2019 |
Guarducci C, Nardone A, Feiglin A, Migliaccio I, Malorni L, Bonechi M, Benelli M, Leo AD, Hodgson G, Shapiro G, Brown M, Jeselsohn R. Abstract PD7-12: Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd7-12 |
0.644 |
|
| 2019 |
Jeselsohn R, Guo H, Rees R, Barry W, Barlett C, Tung N, Krop I, Brown M, Winer E. Abstract PD1-05: Results from the phase Ib/II clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd1-05 |
0.69 |
|
| 2018 |
Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, ... ... Jeselsohn R, et al. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. British Journal of Cancer. PMID 30555156 DOI: 10.1038/S41416-018-0354-9 |
0.629 |
|
| 2018 |
Metzger-Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz-Luis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. The Oncologist. PMID 30518616 DOI: 10.1634/Theoncologist.2018-0363 |
0.332 |
|
| 2018 |
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, et al. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 7. PMID 30489256 DOI: 10.7554/Elife.37161 |
0.752 |
|
| 2018 |
Hinohara K, Wu HJ, Vigneau S, McDonald TO, Igarashi KJ, Yamamoto KN, Madsen T, Fassl A, Egri SB, Papanastasiou M, Ding L, Peluffo G, Cohen O, Kales SC, Lal-Nag M, ... ... Jeselsohn R, et al. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. PMID 30472020 DOI: 10.1016/J.Ccell.2018.10.014 |
0.695 |
|
| 2018 |
Schiff R, Jeselsohn R. Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine. Cancer Discovery. 8: 1352-1354. PMID 30385523 DOI: 10.1158/2159-8290.Cd-18-1084 |
0.318 |
|
| 2018 |
Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Jänne PA, Paweletz CP, Lin NU, Krop IE, Barry WT, Winer EP, ... ... Jeselsohn R, et al. Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer. Npj Breast Cancer. 4: 22. PMID 30083595 DOI: 10.1038/s41523-018-0075-5 |
0.611 |
|
| 2018 |
Xiao T, Li W, Wang X, Xu H, Yang J, Wu Q, Huang Y, Geradts J, Jiang P, Fei T, Chi D, Zang C, Liao Q, Rennhack J, Andrechek E, ... ... Jeselsohn RM, et al. Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29987050 DOI: 10.1073/Pnas.1722617115 |
0.797 |
|
| 2018 |
Cornwell M, Vangala M, Taing L, Herbert Z, Köster J, Li B, Sun H, Li T, Zhang J, Qiu X, Pun M, Jeselsohn R, Brown M, Liu XS, Long HW. VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. Bmc Bioinformatics. 19: 135. PMID 29649993 DOI: 10.1186/S12859-018-2139-9 |
0.432 |
|
| 2018 |
Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, et al. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell. 33: 173-186.e5. PMID 29438694 DOI: 10.1016/J.Ccell.2018.01.004 |
0.691 |
|
| 2018 |
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, et al. Author response: The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells Elife. DOI: 10.7554/Elife.37161.024 |
0.721 |
|
| 2018 |
Fu X, Pereira R, Angelis CD, Veeraraghavan J, Shea M, Nanda S, Feng Q, Jeselsohn R, O'Malley B, Brown M, Osborne C, Schiff R. Abstract P4-04-03: Hyperactive FOXA1 activates super-enhancer-engaged HIF2α/EPAS1 to promote endocrine-resistant metastatic ER-positive breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-04-03 |
0.73 |
|
| 2018 |
Angelis CD, Nardone A, Cataldo M, Veeraraghavan J, Fu X, Giuliano M, Malorni L, Jeselsohn R, Osborne K, Schiff R. Abstract P4-03-05: AP-1 as a potential mediator of resistance to the cyclin-dependent kinase (CDK) 4/6-inhibitor palbociclib in ER-positive endocrine-resistant breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-03-05 |
0.532 |
|
| 2017 |
Jeselsohn R. Are We Ready to Use ESR1 Mutations in Clinical Practice? Breast Care (Basel, Switzerland). 12: 309-313. PMID 29234250 DOI: 10.1159/000481428 |
0.576 |
|
| 2017 |
Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino MF, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani V, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, et al. Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis. Cancer Research. PMID 29212856 DOI: 10.1158/0008-5472.Can-17-1327 |
0.743 |
|
| 2017 |
Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, et al. Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proceedings of the National Academy of Sciences of the United States of America. PMID 28507152 DOI: 10.1073/Pnas.1620993114 |
0.8 |
|
| 2017 |
Jeselsohn R, De Angelis C, Brown M, Schiff R. The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. Current Oncology Reports. 19: 35. PMID 28374222 DOI: 10.1007/S11912-017-0591-8 |
0.66 |
|
| 2017 |
Xiao T, Li W, Wang X, Xu H, Wu Q, Jiang P, Yang J, Fei T, Zang C, Liao Q, Rennhack J, Andrechek E, Li N, Jeselsohn R, Liu SX, et al. Abstract PR06: CRISPR screens identified drivers of endocrine resistance and synthetic lethal vulnerabilities in breast cancer Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Pr06 |
0.751 |
|
| 2017 |
Ligibel J, Irwin M, Dillon D, Barry W, Giobbie-Hurder A, Frank E, Winer E, McTiernan A, Cornwell M, Pun M, Brown M, Jeselsohn R. Abstract S5-05: Impact of pre-operative exercise on breast cancer gene expression Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S5-05 |
0.621 |
|
| 2017 |
Fu X, Pereira R, Zhao D, Jung S, Jeselsohn R, Creighton C, Shea M, Nardone A, Angelis C, Tsimelzon A, Wang T, Gutierrez C, Huang S, Edwards D, Rimawi M, et al. Abstract PD2-04: FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd2-04 |
0.696 |
|
| 2017 |
Kuang Y, Siddiqui B, Hu J, Barry WT, Lin NU, Wagle N, Kirschmeier P, Jänne PA, Paweletz C, Krop I, Winer EP, Brown M, Jeselsohn R. Abstract 4950: The emergence of ESR1 mutations is associated with aromatase inhibitor and fulvestrant therapy Cancer Research. 77: 4950-4950. DOI: 10.1158/1538-7445.Am2017-4950 |
0.579 |
|
| 2016 |
Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, et al. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 113: E6600-E6609. PMID 27791031 DOI: 10.1073/Pnas.1612835113 |
0.716 |
|
| 2016 |
Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, de Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Di Leo A, Malorni L. TransCONFIRM: Identification of a genetic signature of response to fulvestrant in advanced hormone receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27185372 DOI: 10.1158/1078-0432.Ccr-16-0148 |
0.716 |
|
| 2016 |
Jeselsohn R, Brown M. How drug resistance takes shape. Elife. 5. PMID 27010172 DOI: 10.7554/Elife.14973 |
0.557 |
|
| 2016 |
Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, ... Jeselsohn R, et al. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Molecular Cancer Research : McR. PMID 26965145 DOI: 10.1158/1541-7786.Mcr-15-0423 |
0.761 |
|
| 2016 |
Luo F, Le X, Jeselsohn R, Brown M, Garraway L. Abstract P3-05-13: Estrogen-independent growth ofESR1-mutant breast cancer cells requires CDK4/6 Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-05-13 |
0.745 |
|
| 2016 |
Nguyen M, Buchwalter G, Luo F, Garraway L, Brown M, Jeselsohn R. Abstract P3-05-09: Exploring bazedoxifene and palbociclib as potential therapeutic strategies for overcoming ESR1-mediated endocrine resistance Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-05-09 |
0.708 |
|
| 2015 |
Jeselsohn R, Buchwalter G, Angelis C, Brown M, Schiff R. ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nature Reviews. Clinical Oncology. PMID 26122181 DOI: 10.1038/Nrclinonc.2015.117 |
0.681 |
|
| 2015 |
Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, ... ... Jeselsohn RM, et al. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Research : Bcr. 17: 3. PMID 25572662 DOI: 10.1186/S13058-014-0508-5 |
0.374 |
|
| 2015 |
Jeselsohn RM, Barry WT, Zhao J, Buchwalter G, Guarducci C, Migliaccio I, Biagioni C, Bonechi M, Laing N, Rukazenkov Y, Winer EP, Brown M, Leo AD, Malorni L. Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S1-01 |
0.648 |
|
| 2015 |
Fu X, Jeselsohn R, Hollingsworth EF, Lopez-Terrada D, Creighton CJ, Nardone A, Shea M, Heiser LM, Anur P, Wang N, Grasso C, Spellman P, Gutierrez C, Rimawi MF, Hilsenbeck SG, et al. Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-2 |
0.655 |
|
| 2015 |
Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki L, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, ... ... Jeselsohn R, et al. Abstract P4-01-06: Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-01-06 |
0.458 |
|
| 2015 |
Malorni L, Biagioni C, Guarducci C, Bonechi M, Capaccioli G, Jeselsohn R, Barry WT, Laing N, Leo AD, Migliaccio I. 60PAP-2gamma as a novel biomarker of endocrine resistance: Results from the TransCONFIRM study Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv117.22 |
0.353 |
|
| 2014 |
Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1757-67. PMID 24398047 DOI: 10.1158/1078-0432.Ccr-13-2332 |
0.697 |
|
| 2013 |
Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I. D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Research. 73: 6856-64. PMID 24217577 DOI: 10.1158/0008-5472.Can-13-1197 |
0.758 |
|
| 2013 |
Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, Chi D, Fu X, Schiff R, Brown M, Brugge JS. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell. 23: 753-67. PMID 23764000 DOI: 10.1016/J.Ccr.2013.04.026 |
0.8 |
|
| 2013 |
Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come SE. Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. Plos One. 8: e64225. PMID 23741308 DOI: 10.1371/Journal.Pone.0064225 |
0.625 |
|
| 2013 |
Chi D, He H, Yeung T, Jeselsohn R, Schnitt S, Garber J, Richardson A, Lim E, Brown M. Abstract 2313: Differences in estrogen receptor signaling in normal mammary epithelial cells and ER-positive primary breast tumors and metastases. Cancer Research. 73: 2313-2313. DOI: 10.1158/1538-7445.Am2013-2313 |
0.8 |
|
| 2013 |
Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Cristofanilli M, Arteaga C, Balko J, Gilmore L, Schnitt S, Come S, Pusztai L, Stephens P, Miller V, Brown M. Abstract S3-06: Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-S3-06 |
0.728 |
|
| 2012 |
Brown NE, Jeselsohn R, Bihani T, Hu MG, Foltopoulou P, Kuperwasser C, Hinds PW. Cyclin D1 activity regulates autophagy and senescence in the mammary epithelium. Cancer Research. 72: 6477-89. PMID 23041550 DOI: 10.1158/0008-5472.Can-11-4139 |
0.347 |
|
| 2012 |
Jeselsohn R, Regan M, Werner L, Fatima A, He H, Brown M, Iglehart J, Richardson A, Come S. Abstract P1-07-07: Inflammatory gene expression variations in the interval between core needle biopsy and excisional biopsy in early breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P1-07-07 |
0.654 |
|
| 2011 |
Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton C, Lupien M, Hilsenbeck S, Healy N, Mazumdar A, Trivedi M, Jeselsohn R, He H, Fu X, Gutierrez C, Brown M, et al. P4-01-18: AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-01-18 |
0.781 |
|
| Show low-probability matches. |